lifestyle.thedishh.com

Author: MBX Biosciences, Inc.

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

April 28, 2026
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

April 28, 2026
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

March 9, 2026
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

March 9, 2026
MBX Biosciences to Participate in Upcoming March Investor Conferences

February 23, 2026
MBX Biosciences to Participate in Upcoming Investor Conferences

February 12, 2026
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

January 22, 2026